Nanjing King-Friend Biochemical Pharmaceutical | Sustainability Performance
Develops and manufactures biopharmaceutical products, producing generic injectables and active pharmaceutical ingredients for medical use.
2000
China
1,001 - 5,000 employees
Biotechnology
$500M - 1B in revenue
$25M - 100M in profitability
Sustainability Ranking & Industry Benchmark
#2905
Overall#59
in China#48
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$3.9BFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
7.3%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
10.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
3.7
▼ 9.1%
3.9
▼ 7.6%
3.9
▼ 8.3%
5.7
2027Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
29%
Independent Directors
2 out of 7 incl. management
Overall score
18
Environment
13
Social
14
Governance
28
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
